Abnormal lipoprotein metabolism in diabetic nephropathy

Clinical and Experimental Nephrology

Volumn 18, Issue 2, 2014, Pages 206-209

  Hirano, Tsutomu ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apolipoproteins; Diabetic nephropathy; Remnant lipoproteins; Serum amyloid A; Small dense LDL

Indexed keywords

CHYLOMICRON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SERUM AMYLOID A; TRIACYLGLYCEROL; APOLIPOPROTEIN B; LIPOPROTEIN; LIPOPROTEIN TRIGLYCERIDE;

ATHEROGENESIS; DIABETIC NEPHROPATHY; DISORDERS OF LIPOPROTEIN METABOLISM; HEMODIALYSIS PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOPROTEINEMIA; REVIEW; BLOOD; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHIES; METABOLISM; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY;

APOLIPOPROTEINS B; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETIC NEPHROPATHIES; HUMANS; LIPOPROTEINS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SERUM AMYLOID A PROTEIN; TRIGLYCERIDES;

EID: 84899947755     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-013-0880-y     Document Type: Review

References (10)

1. Hirano T, Oi K, Sakai S, et al. High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia. Atherosclerosis. 1998;141:77-85. (Pubitemid 28539418)
2. Hayashi T, Hirano T, Taira T, et al. Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease. Atherosclerosis. 2008;197:154-8. (Pubitemid 351273234)
3. Hirano T, Ookubo K, Kashiwazaki K, et al. Vascular endothelial markers, von Willebrand factor and thrombomodulin index, are specifically elevated in type 2 diabetic patients with nephropathy: comparison of primary renal disease. Clin Chim Acta. 2000;299:65-75. (Pubitemid 30438790)
4. Kashiwazaki K, Hirano T, Yoshino G, et al. Decreased release of lipoprotein lipase is associated with vascular endothelial damage in NIDDM patients with microalbuminuria. Diabetes Care. 1998;21:2016-20. (Pubitemid 28478310)
5. Hirano T, Sakaue T, Misaki A, et al. Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII. Kidney Int. 2003;63:2171-7. (Pubitemid 36605828)
6. Hirano T, Hayashi T, Adachi M, et al. Marked decrease of apolipoprotein A-V in both diabetic and nondiabetic patients with end-stage renal disease. Metabolism. 2007;56:462-3. (Pubitemid 46427841)
7. Hirano T, Furukawa S, Kurokawa M, Ebara T, Dixon JL, Nagano S. Intracellular apoprotein B degradation is suppressed by decreased albumin concentration in Hep G2 cells. Kidney Int. 1995;47:421-31.
8. Hirano T, Naito H, Kurokawa M, et al. High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy. Atherosclerosis. 1996;123:57-72. (Pubitemid 26176575)
9. Hirano T, Nohtomi K, Nakanishi N, et al. Ezetimibe decreases serum amyloid A levels in HDL3 in hemodialysis patients. Clin Nephrol. 2010;74:282-7.
10. Honda H, Ueda M, Kojima S, et al. Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients. Atherosclerosis. 2012;220(2):493-501.